Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines

Daewoong Pharmaceutical

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Crows Feet Lines

Treatments: Drug: Clostridium Botulinum A Toxin

Study type: Interventional

Funder types: Industry

Identifiers

NCT02882893

DW_DWP450005

Details and patient eligibility

About

The purpose of this study is to evaluate the Efficacy and Safety of DWP450 treatment of Crows Feet Lines(CFL).

Enrollment: 238 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Male or female of at least 18 to 75 years old
• Bilaterally symmetrical moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

238 participants in 2 patient groups

DWP450

Experimental group

Description:

Single-dose

Treatment:

Drug: Clostridium Botulinum A Toxin

Drug: Clostridium Botulinum A Toxin

Botox

Active Comparator group

Description:

Single-dose

Treatment:

Drug: Clostridium Botulinum A Toxin

Drug: Clostridium Botulinum A Toxin